Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post-ET/PV Myelofibrosis

Jack W. Singer, M.D.¹, Suliman Al-Fayoumi, Ph.D., M.B.A.¹*, Haiching Ma², Rami S. Komrokji, M.D.³, Ruben Mesa, M.D.⁴ and Srdan Verstovsek, M.D., Ph.D.⁵

¹CTI BioPharma Corp, Seattle, WA; ²Reaction Biology, Malvern, PA; ³Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; ⁴Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ; ⁵Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; *Not a member of ASH

BACKGROUND

Pacritinib, an ATP-binding site multikinase inhibitor with low nM activity against JAK2 and JAK2 V617F, is in Phase 3 development in myelofibrosis.

In preclinical models, and in Phase 1 studies in both non-Hodgkin lymphoma and myelofibrosis, it appeared unique among this class of agents for its lack of myelosuppression at doses that inhibit the JAK2/STAT3 pathway and result in clinical efficacy.

In two Phase 2 studies in myelofibrosis that had no exclusion restriction for thrombocytopenia, pacritinib was effective at reducing spleen size and symptoms regardless of starting platelet counts. There was no apparent treatment-related decline in platelet counts regardless of starting levels.

Pacritinib did not cause worsening anemia or cause an increase in RBC transfusion requirements. There was no apparent non-hematological cumulative toxicity and dose adjustments were rarely required (Verstovsek et al.; Blood 2011).

To help elucidate the mechanisms for pacritinib’s lack of hematopoietic suppression despite its low nM inhibition of JAK2/STAT3, we performed a kinase-wide screen to evaluate its spectrum of kinase inhibition.

KINASE ASSAY METHODS

In vitro profiling of the 429 member kinase panel was performed at Reaction Biology Corporation using the “HotSpot” assay platform (Nature Biotechnology; 29:1039-45, 2011).

For the screening assays, pacritinib was tested at 100 nM. After subtraction of background derived from control reactions containing inactive enzyme, kinase activity data were expressed as the percent remaining kinase activity in test samples compared to DMSO control.

Dose responses from 1-100 nM were performed on all kinases that were inhibited by >50% at 100 nM and curve fits were obtained using Prism (GraphPad Software).

Kinome tree representations were prepared using Kinome Mapper. http://www.reactionbiology.com/apps/kinome/mapper/LaunchKinome.htm

The potential for pacritinib to interfere with microenvironmental-tumor interactions through suppression of c-fms, IRAK1, JAK2 and FLT3. These potential indications are under exploration in ongoing clinical trials.

The potential for pacritinib to interfere with microenvironmental-tumor interactions through suppression of c-fms, IRAK1, JAK2 and FLT3. These potential indications are under exploration in ongoing clinical trials.

DISCUSSION & CONCLUSIONS

• Pacritinib is an oral multikinase inhibitor with specificity for kinases in several unrelated families.

• Steady-state concentrations of up to 200 nM of free pacritinib are achieved with standard dosing and acceptable side effects.

• Pacritinib suppresses all members of the JAK/FLT3 pathways, with the exception of JAK1 at low nM concentrations. It is inactive against JAK1 at 100 nM.

• The inhibition of IRAK1 and c-fms (CSF1R) may contribute to its anti-inflammatory activity and early onset of symptomatic benefit in myelofibrosis.

• Although pacritinib suppresses the JAK2/STAT3 pathway, pacritinib does not cause myelosuppression. We hypothesize that this may be due in part to its ability to decrease production of negative regulators of hematopoiesis through suppression of c-fms and IRAK1.

• The kinase profile of pacritinib suggests its potential therapeutic utility in AML, MDS, and particularly in CMML due to its potent inhibition of c-fms, IRAK1, JAK2 and FLT3. These potential indications are under exploration in ongoing clinical trials.

• The potential for pacritinib to interfere with microenvironmental-tumor interactions through suppression of IRAK1 and c-fms, along with its lack of myelosuppression, suggest its potential for use in combination with established therapies in a variety of liquid and solid tumors.